^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Leiomyosarcoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.
Published date:
05/28/2021
Excerpt:
Seventy-five patients met inclusion criteria. Of these, 25 received a treatment based on identified alterations; 1 had a complete response (CR), 4 had partial responses (PR), and 4 experienced disease stabilization (SD). We identified two patients with MET amplified sarcoma that responded to treatment with crizotinib. One other patient with a diagnosis of leiomyosarcoma was found to have an unusually high total mutational burden (TMB) and experienced complete pathologic response to dual checkpoint blockade...
Source:
Title:
Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.
Published date:
05/19/2021
Excerpt:
One other patient with a diagnosis of leiomyosarcoma was found to have an unusually high total mutational burden (TMB) and experienced complete pathologic response to dual checkpoint blockade....Ipilimumab + Nivolumab – CR, ongoing 1.5+ yrs...
DOI:
10.1200/JCO.2021.39.15_suppl.11538
